MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study

Table 2 Visual rating scores according to diagnosis and amyloid status

Score	Cognitively normal		Mild cognitive impairment		Alzheimer-type dementia
Score	Amyloid negative	Amyloid positive	Amyloid negative	Amyloid positive	Amyloid negative	Amyloid positive
MTA	0 (0–1)	0 (0–1)	0.5 (0–1)	1 (0.5–1.5)^††	1 (0.5–2)	1 (1–2)
GCA	0 (0–1)	0 (0–1)	0 (0–1)	1 (0–1)^††	1 (0–2)	1 (1–1)
Parietal	1 (0–1)	0.5 (0–1)	1 (0–1)	1 (0–1.63)^†	2 (0–2)	1 (1–2)
Fazekas	1 (0–1)	1 (0–1)	1 (0–1)	1 (1–2)	1 (1–1)	1 (0–2)
Microbleeds present	6 (21%)	4 (20%)	29 (25%)	56 (29%)	1 (50%)	17 (22%)

Data presented as median (interquartile range) or count (%)
APOE apolipoprotein E, FDR false discovery rate, GCA global cortical atrophy, MTA medial temporal lobe atrophy
^†p_FDR < 0.05, ^††p_FDR < 0.01, difference between amyloid positive and negative within diagnostic group. Analyses corrected for age, gender, APOE ε4 genotype and cohort

ISSN: 1758-9193